癌症神经病理性疼痛:系统综述、筛查工具性能与症状特征分析
该系统综述评估了LANSS、DN4和PDQ三种神经病理性疼痛筛查工具在癌症患者中的方法学质量与识别性能。六项研究共纳入2301例癌症患者,其中1564例报告疼痛,筛查工具总体准确率范围为73%至94%。临床评估描述与严谨性存在差异,尤其参考标准中临床判断的严谨性不足,可能解释筛查工具敏感性的变异。
要点
- LANSS、DN4和PDQ在癌症疼痛患者中与临床医生诊断具有一致性。
- 筛查工具总体准确率范围为73%至94%,但临床评估标准化不足影响敏感性。
- 在临床诊断标准化验证前,筛查工具可用于识别潜在的癌症神经病理性疼痛病例。
核心结论
- LANSS、DN4和PDQ筛查工具结果与临床医生诊断在癌症疼痛患者中具有一致性。
- 临床评估标准化的不足可能解释筛查工具敏感性的变异。
- 在癌症神经病理性疼痛临床诊断标准化验证前,筛查工具可作为识别潜在病例的实用方法。
研究设计与样本
- 系统文献检索纳入报告在癌症患者中使用LANSS、DN4或PDQ且具有神经病理性或非神经病理性疼痛临床诊断的研究。
- 六项研究共招募2301例癌症患者,其中1564例(68%)报告疼痛。
- 请求个体患者数据以检查描述项特征,获得1351例患者的个体数据。
主要发现
- 筛查工具总体准确率范围为73%至94%。
- 临床评估的描述和严谨性存在变异,尤其与作为参考标准的疼痛临床判断严谨性相关。
- 来自1351例患者的个体数据显示,癌症神经病理性疼痛患者对神经病理性疼痛描述项的选择存在很大变异。
- 在肿瘤相关和治疗相关的癌症疼痛病因中,LANSS和DN4项目所表征的神经病理性疼痛症状特征与非神经病理性疼痛显著不同。
关键数值与推荐
- 筛查工具总体准确率范围为73%至94%。
- 六项研究共2301例癌症患者,1564例(68%)报告疼痛。
- 个体数据来自1351例患者。
临床怎么用
- 在癌症疼痛患者中可使用LANSS、DN4或PDQ筛查工具识别潜在的神经病理性疼痛病例。
- 临床评估应参考神经病理性疼痛分级系统以提高标准化程度。
- 需进一步研究标准化和改善癌症疼痛患者的临床评估。
局限性
- 临床评估的描述和严谨性存在变异,尤其参考标准的临床判断严谨性不足。
- 筛查工具敏感性存在变异,可能与标准化临床评估的不足有关。
- 癌症神经病理性疼痛的临床诊断标准化尚未验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The objectives of this study were to evaluate the methodological quality of rigorous neuropathic pain assessment tools in applicable clinical studies, and determine the performance of screening tools for identifying neuropathic pain in patients with cancer. METHODS: Systematic literature search identified studies reporting use of Leeds Assessment of Neuropathic Symptoms and Signs (LANSS), Douleur Neuropathique en 4 (DN4) or painDETECT (PDQ) in cancer patients with a clinical diagnosis of neuropathic or not neuropathic pain. Individual patient data were requested to examine descriptor item profiles. RESULTS: Six studies recruited a total of 2301 cancer patients of which 1564 (68%) reported pain. Overall accuracy of screening tools ranged from 73 to 94%. There was variation in description and rigour of clinical assessment, particularly related to the rigour of clinical judgement of pain as the reference standard. Individual data from 1351 patients showed large variation in the selection of neuropathic pain descriptor items by cancer patients with neuropathic pain. LANSS and DN4 items characterized a significantly different neuropathic pain symptom profile from non-neuropathic pain in both tumour- and treatment-related cancer pain aetiologies. CONCLUSIONS: We identified concordance between the clinician diagnosis and screening tool outcomes for LANSS, DN4 and PDQ in patients with cancer pain. Shortcomings in relation to standardized clinician assessment are likely to account for variation in screening tool sensitivity, which should include the use of the neuropathic pain grading system. Further research is needed to standardize and improve clinical assessment in patients with cancer pain. Until the standardization of clinical diagnosis for neuropathic cancer pain has been validated, screening tools offer a practical approach to identify potential cases of neuropathic cancer pain.
引用
- Mulvey MR, Boland EG, Bouhassira D, et al. Neuropathic pain in cancer: systematic review, performance of screening tools and analysis of symptom profiles. Br J Anaesth. 2017. PMID: 29121284. doi:10.1093/bja/aex175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。